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Abstract: Honey is a natural product known for its varied biological or pharmacological 
activities—ranging from anti-inflammatory, antioxidant, antibacterial, antihypertensive to 
hypoglycemic effects. This review article focuses on the role of honey in modulating the 
development and progression of tumors or cancers. It reviews available evidence (some of 
which is very recent) with regards to the antimetastatic, antiproliferative and anticancer 
effects of honey in various forms of cancer. These effects of honey have been thoroughly 
investigated in certain cancers such as breast, liver and colorectal cancer cell lines.  
In contrast, limited but promising data are available for other forms of cancers including 
prostate, bladder, endometrial, kidney, skin, cervical, oral and bone cancer cells.  
The article also underscores the various possible mechanisms by which honey may inhibit 
growth and proliferation of tumors or cancers. These include regulation of cell cycle, 
activation of mitochondrial pathway, induction of mitochondrial outer membrane 
permeabilization, induction of apoptosis, modulation of oxidative stress, amelioration of 
inflammation, modulation of insulin signaling and inhibition of angiogenesis. Honey is 
highly cytotoxic against tumor or cancer cells while it is non-cytotoxic to normal cells.  
The data indicate that honey can inhibit carcinogenesis by modulating the molecular 
processes of initiation, promotion, and progression stages. Thus, it may serve as a potential 
and promising anticancer agent which warrants further experimental and clinical studies.  
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1. Introduction 
Cancer refers to an unrestrained growth of cells which may exhibit malignant behavior. It is one of 
the leading causes of death worldwide [1]. The most recent global incidence of cancer was estimated at 
28.8 million in 2008 [2]. This rising prevalence is driven by certain factors, such as the adoption of a 
Western lifestyle in several developing countries, ageing populations, increased awareness and 
improved screenings and diagnosis of cancers [3]. Out of the 7.6 million cancer deaths recorded in 
2008, 2.9 and 4.7 million deaths occurred in economically developed and economically developing 
countries, respectively [1]. The impact of this disease is more visible in developing countries. Several 
environmental factors such as smoking, physical inactivity, infections and diseases including obesity 
and diabetes are key risk factors for cancer [4]. The process of cancer development comprises three 
key stages: initiation, promotion, and progression. Initiation, which is the first stage of carcinogenesis, 
involves irreversible genetic damage and is characterized by accumulation of mutated DNA [5]. This is 
followed by promotion stage which is the proliferation of mutated cells. It is characterized by 
excessive growth of mutated cells and additional genomic alterations of the replicated cells giving rise 
to a benign mass of abnormal cells known as a tumor [6]. Then the progression stage which entails 
metastasis of cancer cells to distant sites (tissues and organs) through the lymphatic or circulatory 
systems [5,6]. Besides the limitations of current cancer management (surgery, chemotherapy and 
radiotherapy), available cytotoxic drugs are not easily affordable and available in some places 
(especially in developing countries), and their use is also associated with a number of undesirable side 
and adverse effects [7,8]. As a consequence, a large proportion of the population prefers to patronize 
complementary and alternative medicine (CAM). Even though CAM has its own limitations, it does 
however have a number of advantages (such as affordability, availability and lower side effects) 
compared to the synthetic or standard drugs [9]. The increased public interest in the utilization of CAM 
can be linked to the increased research data which attribute some health benefits to CAM.  
Generally, CAM refers to diverse treatment approaches (medical products and practices) that are 
not an integral part of standard medicine and may include dietary components, supplements, herbal 
preparations, naturally-derived products and even lifestyle changes [10]. There has been an increased 
awareness and use of CAM among cancer patients [11]. One of such products that have become an 
important component of CAM is honey, a natural substance formed from nectar by honeybees. Honey 
exerts several biological activities such as antibacterial, hepatoprotective, anti-inflammatory, 
hypoglycemic, antioxidant and antihypertensive effects [12–18]. Besides its sugar content 
(monosaccharides, disaccharides and oligosaccharides), honey consists of several biologically active 
constituents such as flavonoids and phenolic compounds, vitamins, trace elements, amino acids and 
proteins as well as certain enzymes including glucose oxidase, invertase and catalase [19,20].  
Even though the use of honey dates back to ancient times, the last decade has witnessed an 
astronomical increase in the amount of research investigating the role of honey in the treatment of 
various diseases, including cancer. These health benefits of honey in treating diverse diseases can be 
attributed to its various pharmacologically active constituents, especially flavonoids and phenolic 
constituents. Some of the flavonoids and phenolic compounds that have been identified in honey 
include chrysin, kaempferol, quercetin, pinobanksin, pinocembrin, luteolin, apigenin, genistein, 
naringenin, hesperetin, p-coumaric acid, gallic acid, ellagic acid, ferulic acid, syringic acid, caffeic acid 
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and vanillic acid [15,21–23]. These honey constituents have been shown to exert anti-inflammatory, 
antioxidant, antiproliferative, antitumor, antimetastatic and anticancer effects [23–26]. The inhibitory 
effect of honey on tumorigenesis and cancerogenesis can therefore be attributed to the presence of 
these flavonoids and phenolic acids. This review article highlights the role of honey in modulating the 
development and progression of tumor or cancer as well as various possible mechanisms by which 
honey may inhibit growth of cancer. Findings on the antimetastatic, antiproliferative and anticancer 
effects of honey in various forms of cancer such as breast and colorectal cancer are discussed. In 
contrast, limited but promising data are available for other forms of cancers including prostate, 
bladder, endometrial, skin, cervical, oral and bone cancer cells. While honey is selectively toxic to 
tumor or cancer cells, it is non-cytotoxic to normal cells. Hence, honey may be used as a cancer 
therapeutic agent or to complement conventional cancer treatments. 
2. Structures of Major Flavonoids and Phenolic Acids in Honey  
Flavonoids refer to a group of biologically active natural products with a 15-carbon (C6-C3-C6) 
structure, comprising two benzene rings joined by a heterocyclic pyrane ring [27]. They are generally 
classified as flavonols (e.g., kaempferol, quercetin and pinobanksin), flavones (e.g., chrysin, luteolin 
and apigenin), flavanones (e.g., pinocembrin, naringenin and hesperetin), isoflavones (e.g., genistein) 
and anthocyanidins [28]. Some flavonoids such as chrysin, genistein, naringenin and luteolin have been 
shown to exhibit estrogenic activity and are often referred to as phytoestrogens [29]. The chemical 
structures of some of the major flavonoids present in many varieties of honey are shown in Figure 1. 
Figure 2 shows the chemical structure of 17-β-estradiol (an endogenous estrogen) revealing its 
similarity to that of the flavonoids. The chemical structures of some of the phenolic acids in honey are 
shown in Figure 3. 
Figure 1. Chemical structures of flavonoids in honey. 
 
Chrysin Kaempferol Quercetin 
 
Pinobanksin Pinocembrin Luteolin 
Molecules 2014, 19 2500 
 
 
Figure 1. Cont. 
Figure 2. Chemical structure of the endogenous estrogen 17-β-estradiol. 
 
Figure 3. Chemical structures of phenolic acids in honey.  
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3. Effects of Honey on the Development and Progression of Tumor and Cancer 
There has been an increase in the number of studies investigating the potential role of honey in the 
prevention of tumor or cancer development and progression. Most of these researches utilize in vitro 
techniques, while a scarcity of studies employ in vivo models. These effects of honey on the development 
or progression of tumors or cancers are highlighted according to the type of tumor or cancer in the 
following subsections. 
3.1. Breast Cancer 
Breast cancer is the major cause of cancer deaths among women globally. It is estimated that about 
12% of women will develop breast cancer in their lifetime [1]. Besides several other factors, the 
circulating levels of estrogens and dysregulated estrogen signaling pathways play a predominant role 
in the development and progression of breast cancer [30]. As a result, breast cancer therapy often 
targets the estrogen receptor (ER)-signaling pathway. There have been some attempts to investigate if 
honey could modulate this important pathway. Tsiapara and colleagues evaluated the potential of 
Greek thyme, pine and fir honey extracts to modulate the estrogenic activity and cell viability of breast 
cancer cells (MCF-7) [31]. The authors found that the honey samples exhibited a biphasic activity in 
MCF-7 cells depending on the concentration—an antiestrogenic effect at low concentrations and an 
estrogenic effect at high concentrations. In the presence of estradiol, thyme and pine honey extracts 
were found to antagonize estrogen activity, while fir honey extract enhanced estrogen activity in  
MCF-7 cells. The study also reported variations on the effects of the three honey extracts on cell 
viability. While the study found no effect of thyme and pine honey on MCF-7 cells, fir honey enhanced 
the viability of MCF-7 cells. These dual effects of honey extracts are mostly likely due to their high 
contents of phenolic compounds such as kaempferol and quercetin. Phenolic compounds are 
phytoestrogens which exert dual actions—both inhibitory and stimulatory effects [28]. Phytoestrogens 
are phytochemicals which are structurally similar to mammalian estrogens and therefore can bind to 
estrogen receptors [32]. They can elicit estrogenic or antiestrogenic effect depending on certain factors 
such as its concentration [32,33]. Quercetin has been reported to elicit apoptotic effects through ER  
α- and ER β-dependent mechanisms [34,35]. It is unclear why only fir honey but not thyme and pine 
honey enhanced the viability of MCF-7 cells. Further studies may reveal differences in the 
composition of these honey samples. It is possible that fir honey contain greater amounts of nutrients 
such as phenolic compounds, amino acids, vitamins, minerals and enzymes especially glucose oxidase 
which generate moderate levels of ROS. All this may enhance the viability of MCF-7 cells. 
The cytotoxic effect of tualang honey has also been demonstrated in the human breast cancer cell 
lines MCF-7 and MDA-MB-231 [36]. The cytotoxicity was evident by increased leakage of lactate 
dehydrogenase (LDH) from the cell membranes. Tualang honey was shown to induce apoptosis and 
reduce mitochondrial membrane potential. The authors also found that honey exerted no cytotoxic 
effect in MCF-10A, a normal breast cell line. This therefore suggests that the cytotoxic effect of 
tualang honey is specific and selective to the breast cancer cell lines. This is important because 
selectivity and specificity are key characteristics of a good chemotherapeutic agent. Unfortunately, 
most anticancer drugs lack these properties. These findings have been recently confirmed in another 
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study which compared the effect of tualang honey with that of tamoxifen (an estrogen receptor 
antagonist) in MCF-7 and MDA-MB-231. In addition to corroborating the previous findings [36],  
the study found that the anti-cancer effect of tualang honey on breast cancer cells was similar to that of 
tamoxifen [37]. Cytotoxic effects on breast cancer cells (MCF-7) have also been reported for Indian 
honey [38]. These studies reveal that honey is able to exert cytotoxicity in both MCF-7 and MDA-MB-231 
which are ER-positive and ER-negative breast cancer cells, respectively. This can be attributed to the 
flavonoids and phenolic compounds in honey. These constituents which are phytoestrogens have been 
shown to stimulate both ER-α and –β subtypes [39]. 
Several studies have also confirmed the antimetastic, antiproliferative and anticancer effects of 
honey on breast tumor or cancer in rodents. In a murine (mammary carcinoma) tumor model, the  
anti-metastatic effect of honey when applied before tumor-cell inoculation has been reported [40].  
The antimetastatic effect of honey may be due to its flavonoids such chrysin which have been shown to 
inhibit the metastatic potential of human breast cancer cells [41]. Similarly, a study investigated the 
antitumor effect of two honey samples containing different phenolic contents against Ehrlich ascites 
and solid carcinoma. Both honeys were found to markedly inhibit the growth of Ehrlich ascites 
carcinoma, but the honey containing higher phenolic content exerted a greater antitumor effect [42]. 
Research carried out by Tomasin and Gomes-Marcondes investigated the effects of combined  
Aloe vera and honey on tumor growth and cell proliferation against Walker 256 carcinoma implant in 
Wistar rats. Both agents were found to suppress tumor growth and inhibit cell proliferation [43]. 
In a recent study, Abd Kadir and colleagues investigated the inhibitory effect of Malaysian tualang 
honey on the development of 7,12-dimethylbenz(α)anthracene (DMBA)-induced breast cancer in rats. 
The researchers found that the untreated DMBA-induced breast cancer rats (control rats) showed 
tumor development much earlier than the honey-treated DMBA-induced breast cancer rats. The control 
rats also showed marked increase of tumor size over a shorter period of time. In contrast, the size 
increment and tumor size were markedly reduced in honey-treated DMBA-induced breast cancer rats 
compared to the untreated cancer rats. The authors also found that the honey-treated cancer rats had 
fewer numbers of tumors than the controls. Though not statistically significant, increasing the dose of 
honey tended towards increased apoptotic index. While most of the honey-treated cancer rats 
developed low or medium grade tumor, the untreated rats had mostly high grade tumors.  
The histological analysis also revealed that the cancer cells from the honey-treated rats were more 
identical, with denser nuclei, while those of the control rats had more pleomorphic cells with more 
prominent nuclei. Other findings include less prominent vasculature around the tumor nodules and 
significantly reduced weights and volumes of the tumor masses (which were smaller, softer and paler 
with spots of necrosis) in honey-treated rats [44]. 
These data suggest that honey exhibits anticancer effect as evident by its antiestrogen activity and 
potential in inducing mitochondrial membrane depolarization and apoptosis in breast cancer cells. The 
antiproliferative and antimetastatic effects of honey are also demonstrated by its ability to suppress 
tumorigenesis and reduce size and number of tumors in DMBA-induced breast cancer in rats. The data 
also support previous observations that the biological or pharmacological effects of honey may vary 
among honey samples and dose-dependent. Additional data, especially emanating from in vivo studies, 
are necessary to support or strengthen the anticancer effect of honey in breast cancer. 
Molecules 2014, 19 2503 
 
 
3.2. Liver Cancer 
Like other cancers, the prevalence of liver cancer is on the rise. A 2005 report estimated that 82% of 
liver cancer cases occurred in developing countries [45]. Hepatocellular carcinoma (HCC) is the most 
predominant liver cancer. The increased incidence of HCC is linked to various factors, mainly infection 
with hepatitis B or hepatitis C virus, as well as diabetes, obesity, hereditary and social risk factors such 
as excessive consumption of alcohol [46]. In spite of considerable advances in the treatment of HCC, 
the quality of life among patients remains very poor. This suggests the need to continuously strive for 
better therapies. The antitumor effects of honey on liver cancer cells have recently been reported in a 
number of studies. Hassan et al. demonstrated that treatment of human hepatocellular carcinoma 
(HepG2) cells with honey markedly reduced the number of viable HepG2 cells and nitric oxide (NO) 
levels, while it enhanced the total antioxidant status (TAS) [47]. Based on these findings, it can be 
speculated that the viability or survival of HepG2 cells is sustained by reactive oxygen species (ROS). 
Moderate levels of ROS enhance cell proliferation, growth and differentiation [48,49]. The reduced levels 
of NO following honey treatment lend credence to this view. By scavenging ROS, honey will 
invariably enhance TAS as shown in this study. Hence, decreased ROS and improved antioxidant 
defenses will consequently lead to inhibition of proliferation as evidenced by the reduced number of 
viable HepG2 cells. A study that investigated the antiproliferative effects of gelam honey on HepG2 
found that the IC50 value of gelam honey towards HepG2 was 25% whereas it was 70% for normal 
human hepatocytes (WRL-68) [50]. This shows gelam honey is selectively cytototoxic to liver cancer 
cells. The study also revealed that gelam honey inhibited the proliferation of HepG2 cells and induced 
apoptosis in HepG2. A similar study evaluated the antiproliferative effect of a mixture of gelam honey 
and Tinospora crispa on HepG2 and WRL-68 cells [51]. The study reported an IC50 value of 42.67% 
in HepG2 cells and none in the WRL-68 cells. The mixture was also found to induce apoptosis in HepG2 
cells. Antiproliferative effect of Thailand pot-honey on HepG2 cells has also been demonstrated [52]. 
A study by Abdel Aziz and colleagues investigated the effects of honey extracts on HepG2 cell 
lines [53]. The authors reported that honey extracts exerted cytotoxic, antimetastatic and anti-angiogenic 
effects in HepG2 cells. These effects were found to vary with different degrees based on the honey 
quality while some honey samples with poor quality did not produce cytotoxic effect. Some of the 
honey extracts were also found to enhance proliferation of cancer cells—an effect that may be due to 
the nutrients such as amino acids, minerals, vitamins and antioxidants in honey. Availability of such 
nutrients may serve as substrate for cellular metabolism in HepG2 cells. The proliferative effect of 
honey may also be due to hydrogen peroxide generated by honey. Peroxide-producing honey has been 
reported to liberate radicals [54]. Several factors may influence the amount of ROS generated by 
honey. For instance, honey samples that contain higher amounts of the enzyme glucose oxidase may 
produce more ROS. Similarly, the duration and techniques of storage may also influence the level of 
ROS formed. Though the concentrations may be small, such small amounts of ROS may stimulate 
cancer cell proliferation. While this potential proliferative effect may likely be suppressed in honey 
rich in phenolic compounds, it may be augmented in honey with low phenolic compounds. This may 
explain the variations of the anticancer properties of the different honey extracts. Findings from Hanaa 
and Shaymaa’s study also confirmed the antitumor effect of honey (which was enhanced by adiponectin) in 
HepG2 cells [55]. A recent study investigated the protective effect of three honey samples of diverse floral 
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origin (rosemary, heather and heterofloral) on mutagens-induced DNA strand breaks in a HepG2  
cell line [56]. The study utilized N-nitrosopyrrolidine (NPYR), N-nitrosodimethylamine (NDMA), 
benzo(a)pyrene (BaP) and 2-amino-1-methyl-6-phenyl-imidazo[4,5-b]pyridine (PhIP) as dietary mutagens. 
The results showed that honey samples protected against DNA damage induced by NPYR, BaP and 
PhIP but not NDMA, whereas artificial honey exerted no such protective effect. The study found an 
association between high phenolic content and protection of HepG2 against mutagens-induced DNA 
damage. The protective effect of honey against mutagens-induced DNA damage in HepG2 can be 
attributed to its antioxidant and free radical scavenging properties. 
There are limited data on the potential inhibitory effects of honey on hepatic tumorigenesis or 
carcinogenesis in vivo. A recent study investigated the effect of honey on the development and 
progression of diethylnitrosamine (DEN)-induced hepatic cancer in rats [57]. After treatment for six 
months, the liver of untreated DEN-injected rats showed a variety of lesions including inflammatory 
lymphocytic infiltration, fatty degeneration with displacement of the nucleus, oedema and injured 
hepatocytes with hyperchromatic nuclei. The liver of DEN-injected rats also showed the presence of 
neoplastic hepatic cells which were polyhedral to round with dense vesicular nuclei. Several strong 
positive stained nuclei for p53 and PCNA expressions were also observed in the liver of untreated 
DEN-injected rats. These abnormalities including neoplastic hepatic cells, stained nuclei for p53 and 
PCNA expressions were considerably reduced in the liver of honey-treated DEN-induced rats. These 
findings suggest that honey has an anticancer effect on liver cancer cells and exerts a protective effect 
against chemical-induced hepatocarcinogenesis in rats. 
3.3. Colorectal Cancer 
Colorectal cancer accounts for about 9% of all cancer cases [58]. It is the third commonest cancer in 
the World and the fourth most frequent cause of death [59]. Environmental factors have been identified 
to play a predominant role in the pathophysiology of colorectal cancer [60]. In spite of advances in its 
treatment, including postoperative care, recurrence and mortality rates remain high [61], hence the 
urgent need to complement the current therapies. A study that investigated the chemopreventive effects 
of gelam and nenas monofloral honeys against colon cancer cell lines (HT 29) found that the honey 
samples inhibited proliferation of colon cancer cells. Both honeys also caused DNA damage in a dose 
dependent manner and suppressed inflammation in H2O2 inflammation-induced colon cancer  
cells [62]. In a recent study, Jaganathan and Mandal investigated the apoptotic effect of some crude 
honey samples in colon cancer cell lines, HCT 15 and HT 29. The study confirmed the antiproliferative 
effect of honey in colon cancer cells as previously reported and also revealed that this effect was 
dependent on the level of phenolic content. The higher the phenolic content, the greater the 
antiproliferative effect against colon cancer cells [63]. In addition to its antiproliferative effect, honey 
also induced apoptosis by causing the depletion of intracellular non-protein thiols. It also reduced the 
mitochondrial membrane potential and increased generation of ROS [64]. Findings from in vivo 
studies have also demonstrated the anticancer effect of honey. Studies by Orsolić et al. showed that 
honey, when applied before tumor-cell inoculation, exerted anti-metastatic effect in a murine tumor 
model with colon carcinoma [40,65]. This suggests that the mice are better protected against tumor 
development when honey is administered before tumor-cell inoculation. In other words, the  
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anti-metastatic effect of honey in this murine tumor model is prophylactic. These findings deserve to 
be investigated further especially using other tumor models. Similarly, the antimetastatic effect of 
honey has been demonstrated in anaplastic colon adenocarcinoma of Y59 rats [66]. Other studies  
have also confirmed the protective effect of honey against methylnitrosourea (MNU)-induced colon 
adenocarcinoma in rats [67]. 
3.4. Prostate Cancer  
A study that investigated the bioactivity of three Greek honeys (thyme, pine and fir honey) on 
prostate cancer cells (PC-3) found marked differences in the effects of honeys on cell viability [31]. 
The study showed that only thyme honey reduced considerably the viability of PC-3 cells while no 
such effect was found for pine and fir honey extracts. Iranian honey has also been shown to induce 
apoptosis and inhibit proliferation of PC-3 cells [26]. These findings suggest that honey exerts 
antiproliferative effect on prostate cancer cells. The data also reveal that not all honey samples exhibit 
antiproliferative effect. This seems to support previous findings that the effect of honey on cell 
proliferation is dependent on the concentration of honey as well as the cancer cell line. 
3.5. Other Forms of Cancer  
Swellam and colleague reported that honey markedly inhibited the proliferation of three human 
bladder cancer cell lines—T24, 253J and RT4, as well as one murine bladder cancer cell line,  
MBT-2 [68]. The authors also investigated the in vivo effect of honey on bladder cancer cells 
implanted subcutaneously in the abdomens of mice. It was shown that administration of 6% and 12% 
honey via intralesional and oral routes significantly inhibited tumor growth. Honey has also been 
reported to inhibit cell proliferation, induce apoptosis, alter cell cycle progression and cause 
mitochondrial membrane depolarization in many other forms of cancer including endometrial cancer 
cells [31], renal cell carcinoma [69], skin cancer cells (melanoma) [70], cervical cancer cell lines [37], 
human non-small cell lung cancer cells [71], mouth cancer cells (oral squamous cell carcinoma) and 
bone cancer cells (osteosarcoma) [72]. In a recently published article, Morales and Haza investigated 
the antiproliferative and apoptotic effects of three crude Spanish honey samples of different floral 
origin (polyfloral, heather and rosemary honey) and those of an artificial honey in HL-60, a human 
peripheral blood promyelocytic leukemia cell line [73]. The researchers reported that all the three 
honey samples induced apoptosis, in a concentration and time dependent-manner. The apoptotic effect 
of the honey samples was also found to be dependent on the levels of their phenolic content. The 
antimetastic effect of honey has also been demonstrated in mice with transplantable tumors [65]. A 
study reported a positive effect of honey ingestion on gastric cancer via induction of apoptosis in 
gastric mucosa [74]. The summary of the effects of honey on the development and progression of 
tumor and cancer is presented in Table 1. The table shows the type of cancer or tumor in which the 
effects of honey have been investigated. It also reveals the key findings on the effects of honey on 
these tumor or cancer cells. 
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Table 1. Effects of honey on the development and progression of tumor and cancer cells. 
Type of tumor/cancer and 
cancer cell type 
Effects of honey (key findings) References 
In vitro studies 
Human breast cancer  
(MCF-7 & MDA-MB-231) 
Antagonizes estrogen activity, inhibits cell proliferation, induces apoptosis, 
reduces mitochondrial membrane potential 
[31,36–38] 
Human liver cancer  
(HepG2) 
Inhibits cell proliferation, suppresses angiogenesis, induces apoptosis, 
protects against mutagen-induced DNA damage 
[47,50,52,53,55,56] 
Human colorectal cancer  
(HT 29, HCT 15 & CT 26)  
Inhibits cell proliferation, induces apoptosis, arrests cell cycle, reduces 
mitochondrial membrane potential, increases generation of ROS, depletes 
intracellular non-protein thiols, induces DNA damage, suppresses inflammation 
[62–64,75] 
Human prostate cancer  
(PC-3)  
Inhibits cell proliferation, induces apoptosis [26,31] 
Human bladder cancer  
(T24, 253J, RT4 & MBT-2) 
Inhibits cell proliferation [68] 
Human kidney cancer  
(Renal cancer cell line)  
Induces apoptosis [69] 
Human oral cancer  
(Oral carcinoma) 
Inhibits cell proliferation [72] 
Human bone cancer 
(Osteosarcoma) 
Inhibits cell proliferation [72] 
Human skin cancer  
(Melanoma cells) 
Inhibits cell proliferation, arrests cell cycle [70] 
Human leukemia Induces apoptosis [73] 
Human endometrial cancer Inhibits cell proliferation [31] 
Human lung cancer NCI-H460 Inhibits cell proliferation [71] 
Human cervical cancer Induces apoptosis, disrupts mitochondrial membrane potential [36] 
In vivo studies 
Walker 256 carcinoma Inhibits cell proliferation, arrests cell cycle, induces apoptosis [43] 
DMBA-induced breast cancer 
in rats 
Delays the development of tumors, reduces the number and size of tumors, 
prevents the development of high grade cancer  
[44] 
Rats with DEN-induced 
hepatic cancer 
Protects against transformation of normal liver cells to neoplastic hepatic 
cells, restores the PCNA and P53 expression 
[57] 
Mice/rats with colon 
carcinoma or adenocarcinoma 
Inhibits formation of metastases and tumor growth [40,65–67] 
Mice implanted with bladder 
cancer cells 
Inhibits tumor growth [68] 
Mice with melanoma Inhibits tumor growth, induces apoptosis [75] 
4. Mechanisms of the Antiproliferative, Antimetastatic and Anticancer Effects of Honey 
Some of the mechanisms by which honey may exert its antiproliferative, antimetastatic and 
anticancer effects are discussed in this section. These include, but are not limited to cell cycle arrest, 
activation of mitochondrial pathway, induction of mitochondrial outer membrane permeabilization, 
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induction of apoptosis, modulation of oxidative stress, amelioration of inflammation, modulation of 
insulin signaling, and inhibition of angiogenesis. 
4.1. Cell Cycle Arrest 
Cell cycle is a series of coordinated events in which cell growth and proliferation are tightly 
controlled. It comprises four sequential phases—G1, S, G2 and M. DNA replication takes place at the S 
phase while the cell divides into two identical daughter cells at the M phase [76]. The G1 and G2 are 
the gap phases between S and M. At the G1 phase, the cells are responsive to extracellular signals by 
progressing towards mitosis or withdrawal from the cell cycle into a quiescent stage known as G0 [77]. 
The regulation of the cell cycle events is under the control of a cascade of protein kinases and 
checkpoints [78]. In cancer cells, the cell cycle becomes dysregulated and this results in uncontrolled 
cell proliferation. Using various cancer cell lines, honey has been documented to induce cell cycle 
arrest. Honey treatment of bladder cancer cell lines was shown to cause a considerable arrest of cell 
cycle in the sub-G1 phase [68]. Recently, Aliyu and colleagues also showed that the cytotoxic effect of 
honey against non-small cell lung cancer cell (NCI-H460) was mediated via arrest of cell cycle at 
G0/G1 phase [79]. Available data reveal that the ability of honey to arrest cell cycle is due to the 
various flavonoids and phenolic compounds in honey. In one of such studies, Pichichero et al. [70] 
found both honey and its constituent chrysin exerted antiproliferative effects in human and murine 
melanoma cells via cell cycle arrest at G0/G1 phase. Besides chrysin, several other phenolics such as 
quercetin and kaempferol which are found in large quantities in honey have also been shown to arrest 
cell cycle at various phases such as G0/G1, G1 and G2/M in human melanoma, renal, cervical, 
hepatoma, colon and oesophageal adenocarcinoma cell lines [80–83]. 
4.2. Activation of the Mitochondrial Pathway 
One of the mechanisms by which chemotherapy and radiotherapy cause cancer cell death is the 
activation of the mitochondrial pathway [84]. Mitochondrial membrane permeabilization is an early 
event in the mitochondrial pathway, also known as intrinsic pathway. The mitochondrial pathway 
involves a series of interactions between several stimuli including nutrients, physical stresses, 
oxidative stress and damage [85], during which several proteins (such as cytochrome c) usually located 
in the intermembrane mitochondria space (IMS) become released resulting in cell death [86]. 
Therefore, compounds or agents such as honey rich in flavonoids that are capable of activating 
mitochondrial pathway and release of proteins such as cytochrome C are considered potential cytotoxic 
agents [87,88]. 
4.3. Induction of Mitochondrial Outer Membrane Permeabilization 
The induction of mitochondrial outer membrane permeabilization (MOMP) leads to leakage of 
intermembrane space proteins into the cytosol and consequently causing cell death [89]. Induction of 
MOMP is a common mechanism of agents with anticancer properties. Honey induces mitochondrial 
membrane permeabilization in various cancer cell lines via reduction of the mitochondrial membrane 
potential [36]. Honey has also been found to augment the apoptotic effect of tamoxifen via increased 
Molecules 2014, 19 2508 
 
 
depolarization of the mitochondrial membrane [37]. Similarly, a study by Jaganathan and Mandal 
found that reduction of mitochondrial membrane potential is an important mechanism of the 
cytotoxicity of Indian honey in HCT-15 and HT-29 colon cancer cells [64]. Flavonoids such as 
quercetin have been shown to cause MOMP [90]. Therefore, it can be inferred that cancer cell death 
induced via MOMP by honey is mediated partly through its flavonoid constituents.  
4.4. Induction of Apoptosis 
Apoptosis is a programmed cell death which helps to regulate cell growth and eliminate damaged 
cells [91]. Several apoptotic pathways are deregulated in cancer cells and this favors their survival and 
immortality [92]. The apoptotic pathway involves MOMP which leads to the release of IMS  
pro-apoptotic proteins such as cytochrome c which in turn activate caspase cascade resulting in 
mitochondrial dysfunction and cell death [93,94]. Treatment of cancer cells with honey was shown to 
cause apoptotic cell death in breast cancer cells via induction of caspase-3/7 and -9 activation [36]. 
Honey was also recently reported to enhance tamoxifen-induced apoptosis by activating caspase-3/7,  
-8 and -9 [37]. The effect of honey has also been demonstrated on several enzymes, genes and 
transcription factors related to apoptosis. Colorectal cancer cell lines HCT-15 and HT-29 treated with 
honey showed down-regulation of poly(ADP-ribose) polymerase (PARP) expression [64]. The PARP 
is an enzyme that plays a vital role in apoptosis and DNA repair [95]. The inhibition of PARP activity 
by honey will prevent DNA repair and thereby contribute to increased cytotoxicity of honey in cancer 
cells. The study further revealed that honey treatment induced or activated caspase-3, p53 and Bax 
expression while it down-regulated Bcl2 expression. Honey has also been shown to exert anti-mutagenic 
effect by inhibiting error-prone repair pathway [96].  
The p53, also known as tumor suppressor p53, is an important transcription factor regularly 
inactivated in many forms of human tumors [97,98]. It mediates tumor suppression by modulating the 
transcription of many genes involved in the regulation of apoptosis [99]. Honey treatment in 
diethylnitrosamine (DEN)-induced carcinogenic rats was reported to be associated with nearly normal 
hepatocytes and few neoplastic cells whereas the untreated carcinogenic rats were characterized by 
severely injured hepatocytes, several neoplastic cells and up-regulated p53 expression [57]. The study 
showed that the antineoplastic effect of honey was mediated via restoration of p53 expression. 
Tomasin et al. who evaluated the effect of honey and Aloe vera on apoptosis in rats with Walker  
256 carcinoma reported that tumors from rats treated with honey and Aloe vera had markedly higher 
Bax/Bcl-2 ratio [43]. Similarly, Fernandez-Cabezudo and colleagues demonstrated the apoptotic effect 
of honey on human breast cancer, murine melanoma and colorectal carcinoma cells. The apoptotic 
effect of honey was found to be mediated via the activation of caspase 9, caspase 3 and down-regulated 
Bcl-2 expression [75]. The apoptotic effect of honey is most likely due to its phenolics. Quercetin has 
been reported to inhibit pancreatic and breast cancer cell growth and induce apoptosis via Bcl-2 
expression downregulation and upregulation of Bax expression [100,101]. Recent evidence reveals that 
chrysin, a key constituent of honey, exerts antimetastatic effect in human breast cancer cells [41]. 
Similarly, chrysin was shown to induce apoptosis through caspase-3 and Bax activation in B16-F1 and 
A375 melanoma cells [102]. The Bcl-2 is an anti-apoptotic protein commonly over-expressed in many 
forms of cancers [103]. On the other hand, Bax is a pro-apoptotic protein. Cancer cells generally have 
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characteristic deregulated or impaired apoptosis resulting from down-regulation of pro-apoptotic 
proteins and/or up-regulation of anti-apoptotic proteins [104]. Hence, these findings reveal that honey 
induces cancer cell death or apoptosis via activation of caspase cascade, induction of p53 and  
up-regulation of pro-apoptotic proteins—Bax and down-regulation of anti-apoptotic proteins such as 
Bcl-2. The data also point to the role of honey flavonoids in the apoptotic effect of honey in cancer cells. 
4.5. Modulation of Oxidative Stress 
The role of reactive oxygen species (ROS) and oxidative stress in cancer growth and inhibition still 
remains controversial. There is evidence in support of dual roles of ROS (stimulatory and inhibitory 
roles) in cancer. Low levels of ROS enhance proliferation of cells [105]. On the other hand, increased 
levels of ROS which cause oxidative damage are well documented in many forms of cancer such as 
colorectal cancer [106], breast cancer [107], lung cancer [108,109] and gastric cancer [110]. Therefore, 
the maintenance of redox homeostasis is important for normal cell growth and proliferation. 
Considering that ROS are double-edged sword, available evidence also suggests that selective 
exposure of cancer cells to increased levels of ROS and/or lipid peroxidation products may result in 
cancer cell death [111,112]. Honey is a potent antioxidant and free radical scavengers [113,114]. 
Several of its biological effects are attributed to its antioxidant properties [14,115,116]. Therefore, the 
inhibitory effect of honey on cancer growth and proliferation may be mediated partly via its 
modulation of oxidative stress.  
Data from Hassan and colleagues’ study indicated that the anti-neoplastic effects of honey and 
Nigella sativa on hepatocellular carcinoma cells were associated with improved antioxidant status [47]. 
On the other hand, Jaganathan and Mandal showed that anticancer effect of honey is mediated via 
increased oxidative stress. The researchers reported that honey treatment caused non-protein thiol 
depletion in HCT-15 and HT-29 colon cancer cells. The antiproliferative effect of honey was  
also shown to be associated with increased generation of ROS. Honey-induced cell death was 
accompanied by DNA fragmentation, which was markedly inhibited by treatment with antioxidant,  
N-acetyl-L-cysteine (NAC) [64]. By and large, these findings indicate honey can inhibit cancer growth 
by modulating oxidative stress—that is, via amelioration or induction of oxidative stress. Whether 
honey exerts anticancer effect via antioxidant or pro-oxidant mechanism seems to largely depend on 
the oxidative stress status in the cancer cells. If survival of cancer cells is dependent on low level of 
ROS and oxidative stress, honey may act as a pro-oxidant to generate more ROS and increase 
oxidative stress. On the other hand, if cancer growth is sustained or enhanced by elevated levels of 
ROS and oxidative stress, honey acts as an antioxidant by scavenging ROS and reducing oxidative 
stress. In both cases, pro-oxidant and antioxidant effects of honey invariably result in cancer cell death. 
These dual effects of honey in cancer cells are mostly likely due to its phenolic constituents. Besides 
their antioxidant properties, phenolic compounds are easily oxidizeable. Beverages which have high 
concentrations of polyphenols and strong antioxidant properties have been reported to generate high 
H2O2 levels upon exposure to air [117]. Besides, following their interactions with transition metal ions 
such as copper, honey phenolic compounds may liberate ROS causing ROS-mediated DNA damage 
and resulting in cell death [118,119]. Several flavonoids and phenolics have been demonstrated to 
induce ROS in cancer cells [120]. However, a recent study revealed that while the concentrations of 
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phenolic compounds play a key role in honey-induced HL-60 cell death, honey did not generate  
ROS and NAC (a potent antioxidant) did not prevent honey-induced cancer cell death [73].  
This suggests that in spite of its high phenolic content, honey can still exert its anticancer effect via  
ROS-independent mechanism(s).  
4.6. Amelioration of Inflammation 
Chronic inflammatory disorders are associated with increased risk of cancer. The development of 
inflammatory-related/induced cancers usually occurs within the vicinity of the affected cells or tissues. 
Colorectal cancer, for example, may develop from ulcerative colitis or inflammatory bowel  
diseases [121]. Infection caused by schistosomes and other parasites may predispose the individual to 
bladder cancers [122]. Likewise oral infections such as caused by human papillomavirus (HPV) may 
lead to oropharyngeal cancer [123]. Inflammation is also an important factor in the pathophysiology of 
many other cancers/malignancies [124,125]. Two important components of the inflammatory pathway 
frequently activated in cancers are mitogen-activated protein kinase (MAPK) and nuclear factor kappa 
B (NF-kB) pathways [126]. Activation of MAPK and/or NF-κB, subsequently results in induction of 
several inflammatory proteins and genes including cyclooxygenase-2 (COX-2), C-reactive protein 
(CRP), lipoxygenase-2 (LOX-2), and pro-inflammatory mediators or cytokines such as interleukin 1 
(IL-1), IL-6 and TNF-α. All these pathways and pro-inflammatory mediators are known to play an 
important role in angiogenesis and inflammatory related etiology of cancer [127,128]. Diverse 
biological processes and events that enhance inflammation can contribute to tumorigenesis because 
chronic inflammation is a key driver of promotion, the second stage of cancer development. On the 
other hand, biological processes and activities that decrease inflammation will not only hinder or limit 
the promotion stage (tumorigenesis) but also prevent the transition of this stage to progression stage 
(carcinogenesis). In other words, amelioration of inflammation can help to prevent both the formation 
of a benign tumor and its progression to malignant cancer. Hence, several researchers are paying more 
attention to the prospect of treating cancer by targeting inflammation [129].  
Batumalaie et al. recently showed the honey treatment reduced the expression of MAPK and NF-κB 
in HIT-T15 cells [130]. Chrysin, commonly found in honey, has also been shown to induce apoptosis 
via modulation of MAPK in B16-F1 and A375 melanoma cells [102]. A study investigated the effect 
of honey flavonoid extract (HFE) on the production of pro-inflammatory mediators by 
lipopolysaccharide-stimulated N13 microglia. The data indicated that HFE markedly suppressed the 
release of pro-inflammatory cytokines including TNF-α and IL-1β [23]. Chrysin was also shown to 
enhance TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis in cancer cell lines [131]. 
Honey also suppressed edema and leukocyte (monocyte and neutrophil) infiltration [132]. Recently, 
evidence has also emerged from in vivo studies demonstrating the anti-inflammatory effect of honey. 
Hussein et al. evaluated the anti-inflammatory effect of honey in rats with carrageenan-induced 
inflammation [133]. The study showed that honey decreased edema in a dose-dependent manner while 
it reduced the plasma levels of inflammatory mediators including IL-6, TNF-α, PGE2 and NO. The 
authors also reported that honey administration inhibited the expression of IL-6, TNF-α, iNOS and 
COX-2 in paw tissue. The anti-inflammatory of honey was found to be comparable to that of 
indomethacin. In their latest findings, the researchers demonstrated that honey markedly attenuated 
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NF-κB translocation to the nucleus and suppressed IκBα degradation [134]. The cytotoxic effect of 
honey against non-small cell lung cancer cell was also reported to be partly mediated via modulation 
of inflammatory cytokines [79]. These findings suggest the anti-inflammatory effect of honey, 
mediated via attenuation of pro-inflammatory mediators and inhibition of NF-κB and MAPK signaling 
pathways, may contribute considerably to the anticancer effect of honey. The anti-inflammatory effect 
of honey can be attributed to its phenolic compounds and flavonoids [15,135,136]. 
4.7. Modulation of Insulin Signaling 
Evidence from epidemiological studies indicates insulin resistance, type 2 diabetes mellitus and 
obesity are major risk factors for different types of tumors or malignancies [137–139]. Research in the 
past few years has implicated the role of insulin receptor (IR) in cancerogenesis [140]. Vincent et al. 
recently demonstrated that small molecule inhibitors that target both the IR and insulin-like growth 
factor-1 receptor (IGF1R) are effective in reducing non-small cell lung cancer cell proliferation [141]. 
Another key component of insulin signaling is the PI3K/Akt. The PI3K/Akt is known for its role in 
modulating the functions of several substrates that regulate cell survival, cell cycle progression and 
cellular growth [142]. The effect of gelam honey extracts on Akt activated insulin signaling pathway in 
HIT-T15 cells under hyperglycemic conditions was recently investigated [130]. The researchers 
reported that the development of insulin resistance was characterized by increased levels of MAPK, 
NF-κB, and insulin receptor substrate 1 (IRS-1) serine phosphorylation while Akt expression and 
insulin contents were markedly reduced. The study showed that pretreatment with gelam honey and 
quercetin extracts improved insulin resistance and insulin content. Honey treatment increased the 
expression of Akt while it reduced the expression of IRS-1 serine phosphorylation, MAPK and NF-κB. 
These findings suggest that honey can modulate insulin signaling. Such an effect may contribute to its 
anticancer effect. Hence, similar studies are necessary in cancer cells. 
4.8. Inhibition of Angiogenesis 
Cancer cells generally are capable of penetrating blood or lymphatic vessels. They are circulated 
and later proliferate at adjacent or distant sites/organs, a process known as metastasis [143]. Metastasis 
requires the growth of the vascular network which is necessary for the provision or delivery of oxygen, 
cellular metabolic substrates including nutrients and even blood containing the immune cells [144]. 
This process of formation of new blood is known as angiogenesis. Angiogenesis is a key event in the 
development, growth, progression and metastasis of tumor/cancer [145]. Recent research has focused 
on several angiogenic factors and their inhibitors in the treatment of cancer [146]. Many studies have 
shown that honey has a debriding effect, promotes epithelization, enhances the growth of granulation 
tissue and promotes angiogenic activity in the vasculature [147–149]. In non-cancer cells, honey may 
stimulate angiogenesis via generation of hydrogen peroxide [150]. The angiogenic effect of honey is 
perhaps beneficial in wound healing. On the other hand, it is possible that honey inhibits angiogenesis 
in cancer cells. The potential anti-angiogenic effect of honey in cancer cells is premised on the 
evidence that honey inhibits cancer cell viability, metastasis and activities of gelatinase and protease. 
This is evident from a study by Abdel Aziz and colleagues who demonstrated that honey exerted  
anti-angiogenic effects in hepatocellular carcinoma HePG2 cell lines [53]. Honey is also rich in 
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polyphenols. Polyphenols from natural products such as red wine and green tea have been shown to 
exert anti-angiogenic and anticancer effects [151–153]. Propolis is another bee product like honey. 
Propolis, like honey, has anticancer effects [154] and it has been shown to inhibit tumor-induced 
angiogenesis [155]. Caffeic acid phenethyl ester (CAPE), chrysin and other cytotoxic constituents of 
honey have been reported to exert anti-angiogenic and anticancer effects [25,135,156]. These data 
therefore indicate that honey can exert it anticancer effect via inhibition of angiogenesis. 
Honey can inhibit the development of cancer by blocking the three main stages of cancerogenesis as 
shown in Figure 4. The various molecular mechanisms or targets by which honey can suppress cancer 
development are shown in Figure 5. 
Figure 4. Honey blockage of the 3 stages of cancerogenesis. 
 
Honey inhibits/suppresses the 3 stages of cancerogenesis at initiation [56,57], proliferation [43,44,63] and 
progression [40,65,66]. 
Figure 5. Molecular mechanisms/targets mediating the antiproliferative, antitumor, 
antimetastatic and anticancer effects of honey. 
 
* Honey may generate ROS (and increase OS) or scavenge ROS (and reduce OS) [47,64]. 
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5. Conclusions 
Honey is a natural product that shows potential effects to inhibit or suppress the development and 
progression of tumor and cancer. Its antiproliferative, antitumor, antimetastic and anticancer effects are 
mediated via diverse mechanisms, including cell cycle arrest, activation of mitochondrial pathway, 
induction of mitochondrial outer membrane permeabilization, induction of apoptosis, modulation of 
oxidative stress, amelioration of inflammation, modulation of insulin signaling, and inhibition of 
angiogenesis in cancer cells. Honey is highly and selectively cytotoxic against tumor or cancer cells 
while it is non-cytotoxic to normal cells. It can inhibit cancerogenesis by modulating or interfering 
with the molecular processes or events of initiation, promotion, and progression stages. It, therefore, 
can be considered a potential and promising anticancer agent which warrants further research—both in 
experimental and clinical studies. 
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